Walk into any store and the cannabis aisle now reads like alphabet soup: CBD, CBG, CBN, delta-8, THCV, full spectrum, broad spectrum, isolate. Every bottle promises calm, sleep, or relief, and most of it is sold with more confidence than the science supports. This is a plain-English, non-hype guide to what these compounds actually are, what THC is and how much of it the law allows in an extract (a limit that changed dramatically at the end of 2025), and what the research genuinely shows versus what is just marketing. The short version, which we will unpack: one CBD medicine is strongly proven for a narrow purpose, almost everything else is preliminary, the market is loosely regulated, and the legal ground just shifted under the whole industry.
The short answer
CBD is a non-intoxicating compound from cannabis. The only strongly proven, FDA-approved use of any cannabinoid supplement-style product is a prescription CBD drug, Epidiolex, for a few rare seizure disorders; for anxiety, pain, and sleep the evidence is early and mixed, not settled. THC is the intoxicating cannabinoid, and until recently federal law allowed hemp extracts with up to 0.3 percent delta-9 THC by dry weight. A November 2025 law rewrote that, moving to a total-THC standard and a tiny per-container cap that bans most intoxicating and lab-made hemp cannabinoids like delta-8. The other minor cannabinoids (CBG, CBN, CBC and the rest) are heavily marketed but mostly studied only in cells and animals so far. And because the consumer market is poorly regulated, product quality and honest labeling vary a lot.
CBD and cannabis extracts: the basics
It all comes from one plant, Cannabis sativa. Legally, that plant is split in two by a single number. Hemp is cannabis low in THC, and marijuana is cannabis high in THC, and the dividing line is a THC percentage set by federal law. The plant produces a family of compounds called cannabinoids, of which CBD (cannabidiol) and THC are the two most abundant, along with aromatic terpenes and other molecules.
A cannabis extract is what you get when those compounds are pulled out of the plant, usually with CO2 or alcohol, and concentrated into an oil. That oil is what fills the tinctures, capsules, gummies, and topicals on the shelf. One important thing this is not: hemp seed oil, the culinary oil pressed from hemp seeds, contains essentially no CBD or THC and is a different product entirely, even though the labels can look confusingly similar. When people say CBD oil, they mean an extract of the flower and leaves, standardized to a certain amount of CBD.
The cannabinoids, one by one
Cannabis makes more than a hundred cannabinoids, but only a handful are sold and talked about. The most useful way to read the list is by two questions: does it get you high, and how strong is the actual human evidence behind the claims. Marketing tends to give every minor cannabinoid a catchy nickname; the science tells a more modest story.
| Cannabinoid | Intoxicating? | Marketed or studied for | Where the evidence stands |
|---|---|---|---|
| CBD (cannabidiol) | No | Seizures, anxiety, pain, sleep | Proven for rare seizures (as the drug Epidiolex); preliminary for the rest |
| THC, delta-9 (tetrahydrocannabinol) | Yes | The main high; nausea, appetite, pain (medical) | Well characterized; better pain and nausea evidence than CBD, but intoxicating |
| CBG (cannabigerol) | No | The "parent" cannabinoid; inflammation, focus | Mostly preclinical and animal studies |
| CBN (cannabinol) | Mildly | Sold as the "sleep" cannabinoid | Very little human trial evidence; a THC breakdown product |
| CBC (cannabichromene) | No | Inflammation, mood, neuroprotection | Preclinical only |
| CBDA, CBGA (raw acids) | No | Nausea, inflammation | Early lab and animal work |
| THCV (tetrahydrocannabivarin) | Dose-dependent | Appetite, metabolic and blood-sugar interest | Preclinical and very early human work |
| Delta-8, delta-10 THC, HHC, THCP | Yes | Legal "high" alternatives to marijuana | Little or no safety data; mostly lab-synthesized; targeted by the 2025 law |
| THCA | No (until heated) | Raw-cannabis wellness | Converts to intoxicating THC when heated; counted under the new total-THC rule |
The honest read of that table is that the confident nicknames outrun the data. Calling CBG the parent cannabinoid is chemically fair (its acid form is the precursor the plant builds the others from), but it does not mean CBG is a proven supplement. Calling CBN the sleep cannabinoid is almost pure marketing: the human trial evidence is thin, and a recent review of these minor phytocannabinoids concluded they are promising but still largely at the preclinical stage. Treat every minor-cannabinoid health claim as a hypothesis until human trials catch up.
What THC actually is
THC, or delta-9-tetrahydrocannabinol, is the cannabinoid responsible for the cannabis high. It binds strongly to the CB1 receptors concentrated in the brain, which produces the intoxication, the altered perception, and the impairment of memory, coordination, and reaction time that make driving under its influence dangerous. It is also the compound that standard drug tests are built to detect, along with its metabolites, which is why even trace-THC products can matter for people who get screened.
THC is not only a recreational molecule, though. In medicine, it and synthetic versions are the basis of approved drugs for chemotherapy-related nausea and appetite loss, and, judged purely on evidence, THC-containing cannabis has stronger support for chronic pain than CBD does. The catch is the intoxication, which is exactly why so much of the consumer market is built around CBD and around trying to get THC-like effects from legal, hemp-derived look-alikes. The recent cannabinoids named delta-8 and delta-10, HHC, and THCP are all attempts to deliver a THC-style experience while staying, at least until recently, on the legal side of the hemp line.
The legal limit, and the 2025 change most guides miss
This is the part where almost every older CBD article is now out of date. For years the rule was simple. The 2018 Farm Bill defined hemp as cannabis containing no more than 0.3 percent delta-9 THC by dry weight, and removed hemp and its derivatives from the list of federally controlled substances. That 0.3 percent delta-9 line is what made hemp-derived CBD legal nationwide, and it is the number most people still quote.
But notice the exact wording: it capped delta-9 THC only. That opened a loophole. Companies learned to chemically convert cheap CBD into intoxicating cannabinoids like delta-8 THC, which were not delta-9 and so slipped through, and to sell products whose total THC was high even when delta-9 stayed under the limit. An entire industry of intoxicating hemp products grew inside that gap.
In November 2025, Congress closed it. As part of a federal funding law, lawmakers rewrote the hemp definition, and the change is sweeping.
| 2018 Farm Bill | November 2025 law | |
|---|---|---|
| What THC is measured | Delta-9 THC only | Total THC (delta-9 plus other THC forms and precursors) |
| The limit | 0.3 percent by dry weight | Total-THC standard, plus a cap of 0.4 mg total THC per finished-product container |
| Delta-8, delta-10, HHC, converted cannabinoids | Effectively allowed (the loophole) | Excluded from hemp; synthesized cannabinoids banned |
| Takes full effect | 2018 | After a one-year transition, in late 2026 |
What this means, and what is still uncertain
Legal analysts expect the new rules to remove the large majority of intoxicating hemp products, and a meaningful share of ordinary CBD products, from the legal market once the transition ends, because the tiny per-container THC cap is one that most full-spectrum products exceed. Delta-8 and similar converted cannabinoids would again fall under federal controlled-substance law.
Two honest caveats. First, the fine details of how the cap is measured and enforced are still being worked out by regulators, so treat the specifics as the current best reading rather than the final word. Second, state law varies enormously and is changing fast; some states banned delta-8 years ago, others are still permissive. None of this is legal advice, and if the legality of a specific product matters to you, check your current state and local rules.
What the studies actually show
Strip away the marketing and the research sorts into a clear hierarchy: one thing is genuinely proven, a few things are plausible but unsettled, and most claims are running ahead of the data.
The one thing that is actually proven
The strongest evidence for any CBD product is narrow and specific: purified CBD reduces seizures in a few rare, severe epilepsy syndromes. In rigorous randomized, placebo-controlled trials, pharmaceutical CBD significantly cut seizure frequency in Dravet syndrome and in Lennox-Gastaut syndrome, which is why the FDA approved the prescription drug Epidiolex (later also for tuberous sclerosis complex). This is real, high-quality evidence. It is also the exception that frames everything else: it took a purified, pharmaceutical-grade, precisely dosed drug and formal trials to earn that approval, which is a very different thing from a gummy of unknown content bought online.
Devinsky O et al., N Engl J Med 2017;376(21):2011-2020 (PMID 28538134); Thiele EA et al., Lancet 2018;391(10125):1085-1096 (PMID 29395273). See Sources.
Anxiety is where consumer interest is highest and the evidence is most tantalizing but still thin. A well-known small trial found that a single dose of CBD reduced anxiety during a simulated public-speaking test in people with social anxiety, and a frequently cited review concluded CBD shows promise across anxiety-related conditions. But these are mostly small, short, or single-dose studies, often using high, precisely controlled doses unlike a typical retail product, and larger, longer trials are still lacking. Promising is the right word; proven is not.
Pain is a case where honesty matters, because the better evidence is for THC-containing cannabis, not CBD alone. A large 2021 systematic review and meta-analysis of medical cannabis and cannabinoids for chronic pain found, at best, small improvements in pain and physical functioning compared with placebo, alongside a meaningful rate of side effects. National scientific reviews have likewise concluded there is substantial evidence for cannabis in chronic pain broadly, while evidence for CBD by itself is much weaker. If you see CBD marketed as a powerful painkiller, the data does not back that.
Sleep is the weakest of the popular claims. Much of the apparent sleep benefit may be secondary to reduced anxiety rather than a direct sleep effect, the dedicated trials are small and inconsistent, and the CBN products sold specifically as sleep aids rest on almost no human evidence at all. For sleep and for stress, the better-studied options are covered in our guides to supplements for sleep and supplements for anxiety and stress, and if it is a sleep-timing issue, our explainer on melatonin.
Full spectrum, broad spectrum, and isolate
These three words describe what else is in the bottle besides CBD, and they matter both for effect and for drug testing.
The three types, quickly
- Full spectrum: CBD plus the plant's other cannabinoids and terpenes, including the legal trace of THC. Carries a small drug-test and, now, legal-cap consideration.
- Broad spectrum: the other compounds are kept, but the THC is removed. A middle path for people who want more than isolate without the THC.
- Isolate: purified CBD and nothing else. No THC, no entourage, the most predictable single ingredient.
The popular argument for full spectrum is the entourage effect, the theory that cannabis compounds work better together than any one does alone. It is a plausible and appealing idea, and there is some supporting laboratory work, but the human clinical evidence is limited, so it is best treated as a reasonable hypothesis rather than a proven reason to pay more. If drug testing is a concern, isolate or broad spectrum is the safer choice, and after the 2025 legal changes, the trace THC in full-spectrum products is also worth watching from a compliance angle.
The problem the industry does not advertise: quality
Because CBD is not regulated as a supplement or a food, no agency routinely verifies what is in the bottle, and independent testing has repeatedly found that the label and the contents do not match. A widely cited analysis of CBD extracts sold online found that the majority were inaccurately labeled, containing meaningfully more or less CBD than claimed, and that some contained THC that was not disclosed. Investigations have also turned up contaminants such as heavy metals and solvents in poorly made products.
This is the single most practical reason to be careful. It is why a certificate of analysis (COA), a recent third-party lab report showing the actual cannabinoid content and screening for contaminants, is not a nice-to-have but the baseline for buying anything in this category at all. A brand that will not show you a current COA for the exact batch is asking you to trust a label that history says is often wrong.
Safety, side effects, and the interaction most people miss
On its own, CBD is generally well tolerated, with the most common effects being drowsiness, dry mouth, diarrhea, reduced appetite, and, at the high doses used in seizure trials, elevations in liver enzymes. It is not considered intoxicating or addictive in the way THC can be. But the safety conversation that gets skipped is about interactions.
The grapefruit rule, and other cautions
Drug interactions are the real risk. CBD inhibits a family of liver enzymes (the CYP450 system, including CYP3A4) that metabolize a large share of prescription drugs, the same broad pathway grapefruit affects. That can raise blood levels of medications including blood thinners, certain statins, some antidepressants, and anti-seizure drugs, turning a normal dose into too much. Anyone on prescription medicine should treat this as a real interaction and check with a doctor or pharmacist first. For the wider picture, see our guide to supplement and drug interactions.
Drug testing. CBD will not get you high, but full-spectrum or mislabeled products containing THC can cause a positive drug test.
Pregnancy and specific groups. CBD is not recommended in pregnancy or breastfeeding, and anyone with liver conditions or on medications with a narrow safety margin should be especially cautious.
It is not a regulated medicine. Outside of prescription Epidiolex, consumer CBD is not an FDA-approved treatment for anything, and it is illegal to sell it with claims that it treats or cures disease. Be skeptical of any product that does.
Frequently asked questions
What does CBD do, and does it actually work?
CBD (cannabidiol) is a non-intoxicating compound from the cannabis plant. The one thing it is genuinely proven to do is reduce seizures in a few rare epilepsy syndromes: a purified prescription CBD medicine, Epidiolex, is FDA-approved for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, backed by strong randomized trials. For the reasons most people actually buy it, anxiety, pain, and sleep, the evidence is much weaker: some small trials and reviews are encouraging, but the studies are often small, short, unblinded, or industry-funded, and major treatment guidelines do not list consumer CBD as a recommended option. So the honest answer is that CBD clearly works for specific seizure disorders as a prescription drug, and everything else is promising but preliminary rather than proven. This article is general information, not medical advice.
Does CBD get you high, and will it show up on a drug test?
CBD itself is non-intoxicating and does not produce the high associated with THC. However, it can still cause a positive drug test. Full-spectrum products legally contain a small amount of THC, and standard drug screens look for THC and its metabolites, so regular use of a full-spectrum product can trigger a positive result. Mislabeled products that contain more THC than stated are another route to a failed test. If drug testing is a concern, a broad-spectrum or isolate product with a certificate of analysis showing no detectable THC lowers the risk, though no consumer product can guarantee a test result.
What is the legal THC limit for hemp, and did the law change?
Under the 2018 Farm Bill, hemp was defined as cannabis containing no more than 0.3 percent delta-9 THC by dry weight, which is what made hemp-derived CBD federally legal. That delta-9-only wording created a loophole that the delta-8 industry used, since other THC forms were not capped. In November 2025, Congress changed the definition through a federal funding law: it moved toward a total-THC standard, added a cap of 0.4 milligrams of total THC per container on finished products, and excluded lab-synthesized or converted cannabinoids such as delta-8, delta-10, and HHC. Analysts expect this to remove most intoxicating hemp products from the legal market, with full effect after a one-year transition in late 2026. State laws also vary and are changing, so this is not legal advice.
What is the difference between CBD, CBG, CBN, and the other cannabinoids?
Cannabis makes more than a hundred cannabinoids. The big two are CBD (non-intoxicating, proven only for certain seizures) and delta-9 THC (the main intoxicating one). The minor cannabinoids are heavily marketed but thinly studied: CBG (cannabigerol, the parent compound), CBN (cannabinol, sold for sleep despite little human evidence), CBC (cannabichromene), THCV, and the raw acidic forms CBDA and CBGA are almost entirely at the preclinical or animal-study stage in humans. Then there are the intoxicating novelties, delta-8 and delta-10 THC and HHC, most of them made by chemically converting CBD, plus THCA, the raw acidic form that becomes THC when heated, and these converted and high-THC compounds are the main target of the 2025 law. In short, catchy labels like the sleep cannabinoid or the parent cannabinoid are marketing, not established human science.
Full spectrum, broad spectrum, or isolate: what is the difference?
These describe what else is in a CBD product besides CBD. Full spectrum contains CBD plus the plant's other cannabinoids and compounds, including the legal trace of THC. Broad spectrum contains the other compounds but has the THC removed. Isolate is purified CBD only, with nothing else. The popular argument for full spectrum is the entourage effect, the theory that cannabis compounds work better together than alone, but the human evidence for that is limited and it remains a hypothesis rather than a proven advantage. Practically: full spectrum carries the small THC and drug-test consideration, isolate avoids THC entirely, and broad spectrum sits in between.
Can you take CBD with your medications, and is it safe?
This is the most underrated risk. CBD inhibits liver enzymes in the CYP450 family (including CYP3A4), the same broad pathway affected by grapefruit, so it can raise blood levels of many common medications, including blood thinners, some statins, antidepressants, and anti-seizure drugs. That is a real interaction risk, not a theoretical one, and it is why anyone on prescription medication should talk to a doctor or pharmacist before using CBD. On its own, CBD is generally well tolerated, with possible drowsiness, dry mouth, diarrhea, or appetite changes, and clinical trials of high-dose CBD have shown liver enzyme elevations. It is not recommended in pregnancy or breastfeeding. Because the consumer market is poorly regulated, choosing a product with a third-party certificate of analysis matters.
The bottom line
Cannabis extracts are one of the most oversold categories in wellness, and also one of the most genuinely interesting, which is a frustrating combination. Read honestly, the picture is this: CBD is a real compound with one strongly proven use, as the prescription drug Epidiolex for rare seizure disorders, and a set of plausible but still-unproven uses for anxiety, pain, and sleep, where the evidence is early and the better pain data actually belongs to THC. The minor cannabinoids that fill today's product menu, CBG, CBN, CBC and the rest, are marketed far beyond what the human research supports. THC is the intoxicating one, and the legal line that defined this whole industry, 0.3 percent delta-9 THC, was rewritten in November 2025 into a stricter total-THC standard that will pull most intoxicating hemp products off the legal market by late 2026. On top of that, the consumer market is loosely regulated, labels are often wrong, and CBD carries a real drug-interaction risk that its marketing rarely mentions. None of that means these compounds are worthless. It means the smart posture is curiosity with both eyes open: know that only the seizure use is proven, insist on a third-party certificate of analysis, take the drug-interaction warning seriously, check your current state law, and treat every other health claim as a hypothesis the science has not finished testing.